The acquisition is expected to strengthen Hologic’s presence in the GYN surgical space and expand its fibroid treatment portfolio with Acessa Health’s Acessa ProVu system.
Acessa ProVu system is a fully integrated laparoscopic system. It is used laparoscopically with ultrasound visualisation within the abdomen to treat fibroids within the uterine wall and on the uterine surface.
It complements Hologic’s MyoSure products, which can be used for hysteroscopic removal of fibroids found in the uterine cavity.
Hologic chairman, president and CEO Steve MacMillan said: “Acessa Health provides best-in-class technology that improves patient outcomes and is an excellent fit with our GYN Surgical business.
“This exciting tuck-in acquisition is consistent with our capital deployment goals, will be accretive to our revenue growth rate and provides an attractive return on invested capital.”
Hologic expects Acessa Health to generate approximately $13m in revenue in the fiscal year 2021.
Acessa Health president, co-founder and CEO Kim Rodriguez said: “The Acessa Health team is exceedingly passionate about providing women with more options to address their symptomatic uterine fibroids.
“Now, under Hologic’s leadership and with their commercial presence, the Acessa ProVu system can more rapidly become the standard of care and greatly benefit more women.”
In a separate development, the US-based medical device company Cerebain Biotech signed a letter of intent to purchase the assets of PKG.
PKG designs, develops and manufactures system-level devices with expertise in human-machine interfaces, focusing on healthcare, industrial, aerospace and government products.